Controlled Substances and Their Schedules: NDPS, CSA, MDA 1971 and the EU Frame

The Controlled Substances Act (CSA), enacted in 1970 as Title II of the US Comprehensive Drug Abuse Prevention and Control Act, organises controlled substances into five schedules based on three criteria: accepted medical use in the United States, abuse potential, and safety or dependence liability. Schedule I substances have high abuse potential and no accepted medical use; Schedule V substances have low abuse potential and accepted medical use, with low dependence risk.

The Drug Enforcement Administration (DEA) administers the scheduling system. Substances can be scheduled by Congress (as cocaine and heroin were when the CSA was enacted), by DEA administrative action (a rulemaking process involving a recommendation from the Food and Drug Administration), or by emergency temporary scheduling under the Emergency Scheduling Authority, which the DEA used extensively between 2012 and 2018 to control synthetic cannabinoids, cathinones, and fentanyl analogues as they emerged.

The five schedules, with forensic examples:

• Schedule I: heroin, lysergic acid diethylamide (LSD), cannabis (marijuana), MDMA, psilocybin, mescaline. High abuse potential, no accepted medical use in treatment in the US. The DEA's 2024 proposal to reschedule cannabis from Schedule I to Schedule III represents the most significant proposed scheduling change since the Act was enacted, but as of mid-2026 this has not been finalised.
• Schedule II: cocaine (accepted medical use as a topical local anaesthetic in ENT surgery), methamphetamine (accepted medical use as Desoxyn for ADHD and obesity), fentanyl, oxycodone, morphine, hydromorphone, methadone, PCP. High abuse potential, but with accepted medical applications.
• Schedule III: buprenorphine, ketamine, anabolic steroids, testosterone. Lower abuse potential than Schedule I/II; accepted medical use.
• Schedule IV: benzodiazepines (diazepam, alprazolam, clonazepam), zolpidem, tramadol. Lower abuse potential than Schedule III.
• Schedule V: cough preparations with less than 200 mg codeine per 100 mL, pregabalin, lacosamide. Lowest abuse potential.

The Federal Analogue Act (FAA), enacted in 1986 as part of the Controlled Substances Analogues Enforcement Act, extends Schedule I controls to any substance substantially similar in chemical structure or pharmacological effect to a Schedule I or II substance, when intended for human consumption. The FAA was the principal tool against the first wave of designer drugs (the methcathinone analogues, the PCP analogues) and was applied to MDMA analogues in the 1990s. Its application requires a forensic chemist to testify about structural and pharmacological similarity, which is why forensic chemistry and pharmacology expert witnesses are often jointly retained in analogue cases.

From an instrumental standpoint, DEA laboratories operate under the DEA Microgram protocols, with GC-MS as the primary confirmatory technique and LC-MS/MS used for increasingly complex casework. Reference standards for scheduling opinions are sourced from Cerilliant (a Sigma-Aldrich company) and Cayman Chemical, both DEA-licensed schedule I/II reference standard distributors. Forensic chemists preparing scheduling opinions for DEA administrative proceedings typically use high-resolution mass spectrometry (Thermo Q Exactive or Bruker timsTOF) and NMR to characterise novel substances at the structural level.

The Misuse of Drugs Act 1971 (MDA 1971) classifies controlled drugs into three classes based primarily on the harm they cause to individuals and to society, following the Advisory Council on the Misuse of Drugs (ACMD) recommendations. The classification carries direct sentencing consequences: Class A carries the most severe penalties (up to life imprisonment for supply, seven years for possession); Class B, up to fourteen years for supply and five for possession; Class C, up to fourteen years for supply and two for possession.

Class A drugs include heroin (diamorphine), cocaine, crack cocaine, MDMA, LSD, mephedrone (as of 2010), psilocybin (magic mushrooms, since 2005), methadone, fentanyl and its analogues. Class B includes amphetamines (including methamphetamine, since 2006), cannabis (returned to Class B in 2009 after a period as Class C), synthetic cannabinoids (most JWH-series and related structures), ketamine (Class B since 2014), tramadol (Class C, upgraded from unscheduled in 2014). Class C includes anabolic steroids, GHB, benzodiazepines including diazepam.

The MDA 1971 controls drugs both by individual name and by generic descriptions. Part I of Schedule 2 to the Act lists named substances; Part II lists generic structural families. This generic approach covers, for example, any compound structurally derived from amphetamine, phenethylamine, piperidine, and related scaffolds under specified structural rules. The Home Office regularly amends Schedule 2 through Statutory Instruments (S.I. designations) to add new substances, typically following an ACMD recommendation.

The Psychoactive Substances Act 2016 (PSA 2016) introduced an additional layer: a blanket prohibition on the production, supply, and importation of any substance capable of producing a psychoactive effect, regardless of whether it is listed in the MDA 1971. Exemptions apply to alcohol, tobacco, medicines, caffeine, and food. The PSA 2016 addresses the novel psychoactive substance treadmill by not requiring a substance to be named before its supply becomes a criminal offence.

Forensic chemists working for the UK Forensic Capability Network (FCN) and Home Office-registered forensic providers such as Eurofins Forensic Services, MFSL (Metropolitan Police), and the Lancashire Scientific Services operate under ACPO and College of Policing standards. FTIR-ATR (Bruker Alpha) is used as a rapid preliminary identification tool for seized tablets; GC-MS (Agilent 7890 with 5977 MSD) and LC-MS/MS (Waters Xevo TQ-S) provide confirmation. Drug reference standards are sourced from the UK-based LGC Standards laboratory (which holds the national CRM authority under UKAS accreditation).

The European Union's legal frame for new psychoactive substances rests on Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, which replaced the earlier 1997 Joint Action. The 2005 Decision established a three-stage process: early warning (a forensic network, Europol, and EMCDDA exchange structural and intelligence data on newly encountered substances); risk assessment (EMCDDA conducts a scientific evaluation and produces a risk-assessment report within six weeks of being asked); and control (the Council may, on the basis of the risk assessment, extend scheduling to all member states simultaneously by a further Council Decision).

In practice, the EMCDDA's early-warning system, operated through the Reitox network of 27 national focal points (one per member state), operates much faster than a formal scheduling review. EMCDDA publishes a "New Psychoactive Substances" report annually. In 2023, the Reitox network detected 135 new substances: synthetic cannabinoids (24), synthetic opioids (19, including several novel nitazene derivatives), cathinones (21), benzodiazepines (14), and a range of other structural classes. The 2021 EU Drugs Strategy and the 2021-2025 EU Action Plan on Drugs have further reinforced EMCDDA's risk-assessment mandate.

The 2021 Regulation (EU) 2021/2282 on Health Technology Assessment provides one additional mechanism: the European Medicines Agency (EMA) and EMCDDA now share data pipelines on substances that have passed phase I or II clinical trials in EU member states, allowing the risk-assessment system to be pre-warned about substances with abuse potential that may be re-marketed as controlled analogues.

From a forensic standpoint, the key operational impact is that a forensic chemistry laboratory in, say, the Netherlands or Germany may encounter a novel structural class and, through the Reitox notification, trigger an EU-wide response within weeks. EMCDDA maintains the European Drug Profiles database, which includes reference mass spectra and chromatographic retention data (primarily GC-MS, but increasingly LC-HRMS) for early-warning substances. The Dutch Forensic Institute (NFI) and BKA (Germany's Federal Criminal Police Office) have been among the most productive contributors to the structural characterisation pipeline for novel synthetic opioids and benzodiazepines.

For the six EU substances that have been emergently controlled since 2020 under the accelerated procedure introduced after the NPS Action Plan: metonitazene (control 2021), isotonitazene (2021), brorphine (2021), nitazene derivatives including etonitazene and clonitazene (2022), and protonitazene (2022). All are potent synthetic opioids.

The divergences between the four frameworks produce real-world complications for forensic chemists involved in transnational cases, mutual legal assistance treaty (MLAT) requests, and the import/export of reference standards.

Cannabis: The deepest divergence. In the US, cannabis remains Schedule I federally (as of mid-2026) despite the DEA's proposed rescheduling to Schedule III and the legalisation in 25 states under state law. In the UK, cannabis is Class B. In India, cannabis preparations are Schedule I under NDPS, but the plant itself (bhang, the leaves and seeds) carries a separate legal status under state excise laws that may permit possession for traditional consumption. NDPS draws a critical distinction: "cannabis (hemp)" covering the leaves, seeds, and stalks, and "ganja" covering the flowering or fruiting tops, with the commercial quantity threshold of 20 kg applying to ganja and 1 kg to hashish but the leaves remaining outside the most serious quantity regime.

Fentanyl: Convergently controlled at the highest tier in all four jurisdictions. In the US, fentanyl is Schedule II (with accepted medical use), which is consequential because its prescription is legal. In the UK, fentanyl is Class A under MDA 1971, with no corresponding Schedule II nuance (the medical-use exception is embedded in the Misuse of Drugs Regulations 2001 as a separate instrument). In India, fentanyl falls under the NDPS psychotropic schedule, and the commercial quantity band is effectively equivalent to morphine. The Sinaloa Cartel's 2023-2024 fentanyl supply chain, documented in US DOJ indictments and the CDC's synthetic opioid mortality data (approximately 74,000 synthetic opioid deaths in the US in 2023), produced transnational seizures subject to all four frameworks simultaneously.

MDMA and the rescheduling question: In August 2024, the US FDA declined to approve MDMA-assisted therapy for PTSD (a recommendation from its advisory panel). This left MDMA as Schedule I. Australia's Therapeutic Goods Administration, by contrast, had permitted psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression from 1 July 2023 under a new Schedule 8 provision (controlled drugs with medical use). Australia's decision is outside the four jurisdictions in this topic but illustrates the policy fragmentation that forensic chemists must track when advising on cross-border cases.

Tramadol: Scheduled differently across all four. In India, tramadol is a Schedule H1 prescription drug under the Drugs and Cosmetics Act 1940 but not listed under NDPS psychotropics, making it a regulatory offence rather than a drug trafficking case. In the US, it is Schedule IV. In the UK, it is Class C (MDA 1971, added by Misuse of Drugs (Amendment) (No. 2) Regulations 2014). In many EU member states, tramadol remains a prescription medicine with varying scheduling status, though EMCDDA has flagged its diversion in West Africa and across North Africa as a growing concern.

The practical consequence for the forensic chemist: when a novel substance arrives in a casework exhibit, the first step is always to check the current scheduling status in the relevant jurisdiction, not just rely on training knowledge. The EMCDDA's drug profiles database, the US DEA Controlled Substances Act database (accessible via the DEA Diversion Control Division website), the UK Home Office drug licensing guidance, and the NCB/NDPS gazette notifications are the four primary reference tools.

A forensic chemistry report in a drug case has two distinct elements: the chemical identification (what the substance is, confirmed by at least one Category A method per SWGDRUG guidelines) and the scheduling opinion (which schedule applies in this jurisdiction). The analytical element is within the forensic chemist's expertise. The scheduling element, in some jurisdictions, is considered a legal opinion and may be the province of the presenting police officer or prosecutor rather than the chemist.

In India, the FSL report typically states the chemical identity and the relevant NDPS schedule entry, and then the investigating agency (NCB or state police) calculates the weight against the quantity band. The court applies the legal consequence. In the US, DEA laboratory reports follow the DEA Microgram format: a one-page report that identifies the substance, its schedule, the net weight, and the purity (where quantified). The chemist's declaration explicitly states the schedule classification. In the UK, Forensic Science Regulator Codes of Practice require the expert report to be clear about what is a fact, what is a scientific opinion based on facts, and what is a statement about legal status, with the latter flagged explicitly as not within the chemist's forensic opinion.

The critical quality-control checkpoint is the reference standard used for identification. For a Schedule I / Class A / NDPS Schedule I substance, the reference standard must itself be controlled under the relevant scheduling regime. In the US, a DEA-licensed Schedule I researcher must procure the standard; in the UK, the laboratory must hold a Home Office Controlled Drugs licence; in India, the NDPS Act requires NCB authorisation for laboratories to hold Schedule I narcotic standards. Cerilliant and Cayman Chemical ship to DEA-licensed US labs and Home Office-licensed UK labs; LGC Standards holds the UK reference standard authority. Indian CFSL and state FSLs source standards through NCB-approved channels or through bilateral research agreements with international organisations such as UNODC.

The SWGDRUG identification tiers (Category A: mass spectrometry, nuclear magnetic resonance, X-ray diffraction; Category B: infrared spectrometry, Raman spectrometry, capillary electrophoresis; Category C: colour tests, TLC) require a minimum of one Category A method for a positive identification. For novel substances where no reference standard is available, an HRMS fragmentation-based structural assignment (supplemented by NMR if available) is the fallback, but the report must note the uncertainty and recommend the result be treated as a putative identification pending reference standard confirmation.